ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

The EMA Grants PRIME Designation to Viralym-M To Treat Viral Infections Linked to Stem Cell Transplant

  According to a recent article in The Pharma Letter, the European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation to Viralym-M based on positive results from a Phase 2 proof-of-concept…

Continue Reading The EMA Grants PRIME Designation to Viralym-M To Treat Viral Infections Linked to Stem Cell Transplant
Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)
source: pixabay.com

Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)

By Natalie Homan from In the Cloud Copy Most people have heard of type 1 and type 2 diabetes. Many do not know, however, that there is an “intermediate” form…

Continue Reading Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)
Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
source: pixabay.com

Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants

By Rachel Whetstone from In The Cloud Copy Many patients with myelodysplastic syndromes (MDS) are elderly when they’re diagnosed with the disease. Although stem cell transplants are often thought to…

Continue Reading Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
Pancreatic Cancer: Researchers are Calling Patients’ Response to this Treatment “Unprecedented“
source: pixabay.com

Pancreatic Cancer: Researchers are Calling Patients’ Response to this Treatment “Unprecedented“

  The ASCO Post recently reported findings of high response rates and improved survival from the combination of platinum-based cisplatin and gemcitabine (chemotherapy) in BRCA/PALB2 mutation positive pancreatic ductal adenocarcinoma. The goal…

Continue Reading Pancreatic Cancer: Researchers are Calling Patients’ Response to this Treatment “Unprecedented“